Scottish Medicines Consortium

Scottish Medicines Consortium
Name	Scottish Medicines Consortium
Formation	2001
Type	Health technology assessment body
Headquarters	Edinburgh
Region served	Scotland
Leader title	Chair
Leader name	Professor Andrew McAuley
Parent organisation	NHS Scotland

Scottish Medicines Consortium is the national health technology assessment body for pharmaceuticals in Scotland, providing advice to NHS boards and NHS Scotland on the clinical and cost-effectiveness of new pharmaceutical products and licensed medicines. It operates alongside bodies such as National Institute for Health and Care Excellence, Health Technology Assessment international, European Medicines Agency and interacts with regulators including Medicines and Healthcare products Regulatory Agency and the European Commission. The Consortium's appraisals influence implementation in Scottish NHS Greater Glasgow and Clyde, NHS Lothian, NHS Tayside and other territorial health boards.

History

The organisation was established in 2001 following policy developments after the devolution of powers to the Scottish Parliament and in response to debates involving Scottish Executive, stakeholders from the Association of British Pharmaceutical Industry, and professional bodies such as the Royal College of Physicians of Edinburgh and the Royal Pharmaceutical Society of Great Britain. Early work built on precedents set by agencies like the National Institute for Health and Clinical Excellence and drew on methods from Health Technology Assessment literature shaped by centres such as the University of York and the Cochrane Collaboration. Over time the Consortium evolved its remit during administrations led by First Ministers including Jack McConnell, Alex Salmond, and Nicola Sturgeon, and adapted to regulatory change following the UK's withdrawal from the European Union.

Role and functions

The Consortium issues rapid and full advice to inform adoption of licensed medicines across territorial boards including NHS Ayrshire and Arran and NHS Fife. It advises ministers in the Scottish Government and liaises with procurement bodies such as NHS National Procurement and specialist commissioners like Healthcare Improvement Scotland. Its published advice affects formularies, prescribing practice in primary care networks, and aligns with outcome frameworks used by organisations such as Healthcare Improvement Scotland and audit programmes run by the Public Health Scotland analytic teams. The body also engages with patient groups including Cancer Research UK, disease-specific charities like Parkinson's UK and professional societies such as the British Medical Association.

Decision-making process

Decisions are informed by submissions from pharmaceutical companies that have sought a licence from regulators such as the Medicines and Healthcare products Regulatory Agency and from evidence providers including academic centres at University of Edinburgh, University of Glasgow, and University of Aberdeen. Appraisals are undertaken by clinical and health economics panels including specialists from NHS boards, the Royal College of General Practitioners, and representatives from patient organisations like Macmillan Cancer Support. The process mirrors structures used by international agencies such as IQWiG in Germany and the Canadian Agency for Drugs and Technologies in Health, and culminates in published advice after consideration by the Consortium's board chaired by figures comparable to chairs of bodies like the National Institute for Health and Care Excellence.

Assessments and criteria

Assessments consider clinical effectiveness evidence from randomised controlled trials often conducted by companies such as GlaxoSmithKline, AstraZeneca, Pfizer, Roche, and Novartis and systematic reviews from groups like the Cochrane Collaboration. Economic evaluation uses cost-utility analysis with quality-adjusted life years (QALYs) and compares interventions against NHS comparators used in analyses by the University of York Centre for Reviews and Dissemination and the National Institute for Health Research. Criteria include unmet need as highlighted by charities such as Muscular Dystrophy UK and British Heart Foundation, patient-reported outcomes aligned with work by the National Institute for Health and Care Excellence and safety profiles identified by the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency.

Funding and implementation

The Consortium's work is funded through allocations within NHS Scotland derived from budgets overseen by the Scottish Government and operational budgets across boards including NHS Highland and NHS Grampian. Implementation of positive advice often requires local commissioning decisions involving regional procurement teams and specialist services such as those at Beatson West of Scotland Cancer Centre and the Royal Infirmary of Edinburgh. For high-cost or specialised therapies, arrangements mirror managed entry schemes and risk-sharing agreements seen in other jurisdictions, sometimes involving industry-supported patient access schemes negotiated with suppliers like Janssen, Bristol Myers Squibb, and Eli Lilly.

Governance and organisation

The Consortium is governed by a board with clinical, pharmacy and health economics expertise drawn from NHS organisations and academic institutions including King's College London collaborators and Scottish universities. Operationally it includes assessment teams, patient and public involvement units, and liaison officers who engage with stakeholders such as the British Pharmaceutical Industry (BPI) and patient advocacy groups. Accountability frameworks link to audit and scrutiny by bodies such as Audit Scotland and policy oversight by the Scottish Government health directorates, while collaboration occurs with UK-wide and international partners including NICE and the World Health Organization.

Category:Health technology assessment Category:Healthcare in Scotland Category:Pharmaceutical policy